Logo image of ZYUS.CA

ZYUS LIFE SCIENCES CORP (ZYUS.CA) Stock Fundamental Analysis

Canada - TSX Venture Exchange - TSX-V:ZYUS - CA9899601095 - Common Stock

0.68 CAD
0 (0%)
Last: 1/6/2026, 7:00:00 PM
Fundamental Rating

0

ZYUS gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 32 industry peers in the Pharmaceuticals industry. ZYUS may be in some trouble as it scores bad on both profitability and health. ZYUS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

ZYUS had negative earnings in the past year.
ZYUS had a negative operating cash flow in the past year.
ZYUS had negative earnings in 4 of the past 5 years.
In the past 5 years ZYUS always reported negative operating cash flow.
ZYUS.CA Yearly Net Income VS EBIT VS OCF VS FCFZYUS.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M

1.2 Ratios

Looking at the Return On Assets, with a value of -311.03%, ZYUS is doing worse than 90.63% of the companies in the same industry.
Industry RankSector Rank
ROA -311.03%
ROE N/A
ROIC N/A
ROA(3y)-112.26%
ROA(5y)-68.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ZYUS.CA Yearly ROA, ROE, ROICZYUS.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600

1.3 Margins

ZYUS has a Gross Margin of 13.12%. This is in the lower half of the industry: ZYUS underperforms 68.75% of its industry peers.
ZYUS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 13.12%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZYUS.CA Yearly Profit, Operating, Gross MarginsZYUS.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K

0

2. Health

2.1 Basic Checks

ZYUS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ZYUS has been increased compared to 1 year ago.
The number of shares outstanding for ZYUS has been increased compared to 5 years ago.
The debt/assets ratio for ZYUS is higher compared to a year ago.
ZYUS.CA Yearly Shares OutstandingZYUS.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ZYUS.CA Yearly Total Debt VS Total AssetsZYUS.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -28.00, we must say that ZYUS is in the distress zone and has some risk of bankruptcy.
ZYUS has a worse Altman-Z score (-28.00) than 90.63% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -28
ROIC/WACCN/A
WACC7.84%
ZYUS.CA Yearly LT Debt VS Equity VS FCFZYUS.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

ZYUS has a Current Ratio of 0.10. This is a bad value and indicates that ZYUS is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.10, ZYUS is not doing good in the industry: 90.63% of the companies in the same industry are doing better.
A Quick Ratio of 0.07 indicates that ZYUS may have some problems paying its short term obligations.
ZYUS's Quick ratio of 0.07 is on the low side compared to the rest of the industry. ZYUS is outperformed by 90.63% of its industry peers.
Industry RankSector Rank
Current Ratio 0.1
Quick Ratio 0.07
ZYUS.CA Yearly Current Assets VS Current LiabilitesZYUS.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

1

3. Growth

3.1 Past

ZYUS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.18%, which is quite good.
ZYUS shows a small growth in Revenue. In the last year, the Revenue has grown by 2.88%.
EPS 1Y (TTM)13.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.36%
Revenue 1Y (TTM)2.88%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-14.63%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y18.34%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year16.77%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ZYUS.CA Yearly Revenue VS EstimatesZYUS.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2023 2024 2025 100K 200K 300K 400K 500K
ZYUS.CA Yearly EPS VS EstimatesZYUS.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 -0.1 -0.2 -0.3 -0.4

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ZYUS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ZYUS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZYUS.CA Price Earnings VS Forward Price EarningsZYUS.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZYUS.CA Per share dataZYUS.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for ZYUS!.
Industry RankSector Rank
Dividend Yield 0%

ZYUS LIFE SCIENCES CORP

TSX-V:ZYUS (1/6/2026, 7:00:00 PM)

0.68

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-27 2025-11-27
Earnings (Next)N/A N/A
Inst Owners0.17%
Inst Owner ChangeN/A
Ins Owners8.02%
Ins Owner ChangeN/A
Market Cap53.05M
Revenue(TTM)465.00K
Net Income(TTM)-33.74M
Analysts80
Price Target1.53 (125%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)11.39%
Min Revenue beat(2)3.96%
Max Revenue beat(2)18.81%
Revenue beat(4)3
Avg Revenue beat(4)8.28%
Min Revenue beat(4)-2.54%
Max Revenue beat(4)18.81%
Revenue beat(8)6
Avg Revenue beat(8)7.16%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)9%
Revenue NQ rev (3m)9%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 114.08
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.47
EYN/A
EPS(NY)-0.38
Fwd EYN/A
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS0.01
BVpS-0.17
TBVpS-0.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -311.03%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 13.12%
FCFM N/A
ROA(3y)-112.26%
ROA(5y)-68.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.35%
Cap/Sales 2.15%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.1
Quick Ratio 0.07
Altman-Z -28
F-Score2
WACC7.84%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.36%
EPS Next Y18.34%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)2.88%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-14.63%
Revenue Next Year16.77%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y18.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year99.93%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y17.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y17.17%
OCF growth 3YN/A
OCF growth 5YN/A

ZYUS LIFE SCIENCES CORP / ZYUS.CA FAQ

What is the fundamental rating for ZYUS stock?

ChartMill assigns a fundamental rating of 0 / 10 to ZYUS.CA.


Can you provide the valuation status for ZYUS LIFE SCIENCES CORP?

ChartMill assigns a valuation rating of 0 / 10 to ZYUS LIFE SCIENCES CORP (ZYUS.CA). This can be considered as Overvalued.


How profitable is ZYUS LIFE SCIENCES CORP (ZYUS.CA) stock?

ZYUS LIFE SCIENCES CORP (ZYUS.CA) has a profitability rating of 0 / 10.


What is the financial health of ZYUS LIFE SCIENCES CORP (ZYUS.CA) stock?

The financial health rating of ZYUS LIFE SCIENCES CORP (ZYUS.CA) is 0 / 10.